Miles Wang departs OpenAI to launch an AI drug discovery startup. He targets a $200 million funding round at a staggering $2 billion valuation. The core objective focuses on drug repurposing. Neural networks will analyze existing FDA-approved compounds to bypass grueling safety trials. Wang previously evaluated how models automate scientific discovery [1]. Venture capitalists currently hallucinate. They throw billions at life sciences startups, confusing algorithmic promises with biological reality. The market exhibits pure euphoria. Yet, the underlying engineering truth remains unforgiving. Predicting molecular interactions demands flawless data pipelines and robust model architectures – not just massive compute budgets. A $2 billion valuation guarantees absolutely nothing when the foundational AI architecture fails to map complex biological pathways accurately. Investors fund these...
